HR Execs on the Move

Offsite Care Resources

www.offsitecare.com

 
Offsite Care Resources is a Sebastopol, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Accent Biomedical

Accent Biomedical is a Stow, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Solace Pediatric Healthcare

Solace Pediatric Healthcare is a leading provider of pediatric occupational, physical, speech and feeding therapy services in the state of Colorado. They offer in-home and telehealth therapy services for infants and children with developmental delays o...

BDM Information Systems

BDM Information Systems Ltd. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Clinical Resolution Lab

Clinical Resolution Lab is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic